Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC) Meeting Abstract
| Authors: | Paz-Ares, L.; Owonikoko, T. K.; Johnson, M.; Govindan, R.; Izumi, H.; Lai, V.; Borghaei, H.; Boyer, M.; Boosman, R. J.; Hummel, H. D.; Blackhall, F.; Dowlati, A.; Zhang, Y.; Mukherjee, S.; Sable, B.; Pati, A.; Shetty, A.; Sadraei, N. H.; Champiat, S. |
| Abstract Title: | Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC) |
| Meeting Title: | European Lung Cancer Virtual Congress (ELCC 2021 Virtual) |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 16 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2021 Mar 25-27 |
| Meeting Location: | Virtual Conference |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-04-01 |
| Start Page: | S720 |
| End Page: | S721 |
| Language: | English |
| ACCESSION: | WOS:000634855900049 |
| PROVIDER: | wos |
| DOI: | 10.1016/S1556-0864(21)01890-6 |
| Notes: | Meeting Abstract: 48MO -- Source: Wos |
